{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T07:14:54Z","timestamp":1788160494602,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-026-00595-0","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T03:26:49Z","timestamp":1772594809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of potential drug interactions in rheumatology: a comparative study of decision support software"],"prefix":"10.1007","volume":"34","author":[{"given":"Yeliz","family":"\u015eahin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huri Beyza","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helin","family":"Okumu\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"\u00c7akmak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunus Emre","family":"Ayhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bet\u00fcl","family":"\u00d6zgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senem","family":"\u015ea\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Yunus","family":"Bektay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"6","key":"595_CR1","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/annrheumdis-2017-212565","volume":"77","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, et al. Common Language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the Lay public, healthcare providers and other stakeholders endorsed by the European league against rheumatism (EULAR) and the American college of rheumatology (ACR). Ann Rheum Dis. 2018;77(6):829\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"595_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/ar2669","volume":"11","author":"SE Gabriel","year":"2009","unstructured":"Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11(3):229.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"595_CR3","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1159\/000493390","volume":"27","author":"J Bullock","year":"2018","unstructured":"Bullock J, et al. Rheumatoid arthritis: A brief overview of the treatment. Med Principles Pract. 2018;27(6):501\u20137.","journal-title":"Med Principles Pract"},{"issue":"5","key":"595_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.reumae.2024.02.010","volume":"20","author":"R Lozano-Lozano","year":"2024","unstructured":"Lozano-Lozano R, et al. Prevalence of polypharmacy and drug interaction in older adults with rheumatic disease. Reumatolog\u00eda Cl\u00ednica (English Edition). 2024;20(5):249\u201353.","journal-title":"Reumatolog\u00eda Cl\u00ednica (English Edition)"},{"issue":"6","key":"595_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.farma.2009.09.010","volume":"34","author":"E Arroyo","year":"2010","unstructured":"Arroyo E, Borrallo M, Hern\u00e1ndez C. Detecci\u00f3n y evaluaci\u00f3n de Las interacciones potenciales Entre medicamentos En Una Unidad farmac\u00e9utica de Pacientes externos. Farm Hosp. 2010;34(6):317\u20138.","journal-title":"Farm Hosp"},{"key":"595_CR6","doi-asserted-by":"publisher","first-page":"101373","DOI":"10.1016\/j.cegh.2023.101373","volume":"23","author":"SK Sah","year":"2023","unstructured":"Sah SK, Ramaswamy S, Ramesh M. Assessment of potential drug-drug interactions and their associated risk factor in patients with rheumatoid arthritis: A cross-sectional study. Clin Epidemiol Global Health. 2023;23:101373.","journal-title":"Clin Epidemiol Global Health"},{"issue":"1","key":"595_CR7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1590\/S0482-50042011000100003","volume":"51","author":"F Bagatini","year":"2011","unstructured":"Bagatini F, et al. Potential drug interactions in patients with rheumatoid arthritis. Rev Bras Reumatol. 2011;51(1):20\u201339.","journal-title":"Rev Bras Reumatol"},{"issue":"3","key":"595_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.4103\/MJBL.MJBL_51_22","volume":"19","author":"ZM Al-Ghazaly","year":"2022","unstructured":"Al-Ghazaly ZM, Jassim NAL. Polypharmacy and potential Drug\u2013Drug interactions in patients with rheumatoid arthritis. Med J Babylon. 2022;19(3):396\u2013403.","journal-title":"Med J Babylon"},{"key":"595_CR9","unstructured":"Whalen K. Lippincott\u00ae illustrated reviews: pharmacology. Wolters kluwer india Pvt Ltd.; 2018."},{"issue":"1","key":"595_CR10","doi-asserted-by":"publisher","first-page":"e0276277","DOI":"10.1371\/journal.pone.0276277","volume":"18","author":"MF Rasool","year":"2023","unstructured":"Rasool MF, et al. Assessment of risk factors associated with potential drug-drug interactions among patients suffering from chronic disorders. PLoS ONE. 2023;18(1):e0276277.","journal-title":"PLoS ONE"},{"issue":"1","key":"595_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00228-017-2357-5","volume":"74","author":"WY Zheng","year":"2018","unstructured":"Zheng WY, et al. Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2018;74(1):15\u201327.","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 1","key":"595_CR12","doi-asserted-by":"publisher","first-page":"S204","DOI":"10.12980\/APJTB.4.2014C1172","volume":"4","author":"AS Bhagavathula","year":"2014","unstructured":"Bhagavathula AS, et al. Prevalence of potential drug-drug interactions among internal medicine ward in university of Gondar teaching Hospital, Ethiopia. Asian Pac J Trop Biomed. 2014;4(Suppl 1):S204\u20138.","journal-title":"Asian Pac J Trop Biomed"},{"issue":"2","key":"595_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jsps.2015.03.009","volume":"24","author":"G Murtaza","year":"2016","unstructured":"Murtaza G, et al. Assessment of potential drug-drug interactions and its associated factors in the hospitalized cardiac patients. Saudi Pharm J. 2016;24(2):220\u20135.","journal-title":"Saudi Pharm J"},{"issue":"1","key":"595_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11096-015-0213-1","volume":"38","author":"R Lenssen","year":"2016","unstructured":"Lenssen R, et al. Analysis of drug-related problems in three departments of a German university hospital. Int J Clin Pharm. 2016;38(1):119\u201326.","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"595_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40266-019-00640-5","volume":"36","author":"M Sharma","year":"2019","unstructured":"Sharma M, et al. Clinical outcomes associated with Drug-Drug interactions of oral chemotherapeutic agents: A comprehensive Evidence-Based literature review. Drugs Aging. 2019;36(4):341\u201354.","journal-title":"Drugs Aging"},{"key":"595_CR16","doi-asserted-by":"publisher","first-page":"1088900","DOI":"10.3389\/fphar.2023.1088900","volume":"14","author":"Z O\u010dovsk\u00e1","year":"2023","unstructured":"O\u010dovsk\u00e1 Z, Ma\u0159\u00edkov\u00e1 M, Vl\u010dek J. Potentially clinically significant drug-drug interactions in older patients admitted to the hospital: A cross-sectional study. Front Pharmacol. 2023;14:1088900.","journal-title":"Front Pharmacol"},{"issue":"3","key":"595_CR17","doi-asserted-by":"publisher","first-page":"ofz051","DOI":"10.1093\/ofid\/ofz051","volume":"6","author":"L Demessine","year":"2019","unstructured":"Demessine L, et al. Risk and cost associated with Drug-Drug interactions among aging HIV patients receiving combined antiretroviral therapy in France. Open Forum Infect Dis. 2019;6(3):ofz051.","journal-title":"Open Forum Infect Dis"},{"key":"595_CR18","first-page":"2079","volume":"9","author":"TM Alhawassi","year":"2014","unstructured":"Alhawassi TM, et al. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging. 2014;9:2079\u201386.","journal-title":"Clin Interv Aging"},{"issue":"1","key":"595_CR19","doi-asserted-by":"publisher","first-page":"22598","DOI":"10.1038\/s41598-021-01551-5","volume":"11","author":"AU Rehman","year":"2021","unstructured":"Rehman AU, et al. Humanistic and socioeconomic burden of COPD patients and their caregivers in Malaysia. Sci Rep. 2021;11(1):22598.","journal-title":"Sci Rep"},{"issue":"12","key":"595_CR20","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/00005650-200212000-00004","volume":"40","author":"PA Glassman","year":"2002","unstructured":"Glassman PA, et al. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care. 2002;40(12):1161\u201371.","journal-title":"Med Care"},{"issue":"10","key":"595_CR21","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/11532340-000000000-00000","volume":"33","author":"PL Smithburger","year":"2010","unstructured":"Smithburger PL, Kane-Gill SL, Seybert AL. Drug-drug interactions in cardiac and cardiothoracic intensive care units: an analysis of patients in an academic medical centre in the US. Drug Saf. 2010;33(10):879\u201388.","journal-title":"Drug Saf"},{"issue":"4","key":"595_CR22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/j.1875-9114.2012.01024.x","volume":"32","author":"LE Hines","year":"2012","unstructured":"Hines LE, Malone DC, Murphy JE. Recommendations for generating, evaluating, and implementing drug-drug interaction evidence. Pharmacotherapy. 2012;32(4):304\u201313.","journal-title":"Pharmacotherapy"},{"key":"595_CR23","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.psychres.2019.03.041","volume":"275","author":"S Monteith","year":"2019","unstructured":"Monteith S, Glenn T. A comparison of potential psychiatric drug interactions from six drug interaction database programs. Psychiatry Res. 2019;275:366\u201372.","journal-title":"Psychiatry Res"},{"key":"595_CR24","doi-asserted-by":"crossref","unstructured":"Bektay MY et al. An Assessment of Different Decision Support Software from the Perspective of Potential Drug-Drug Interactions in Patients with Chronic Kidney Diseases.\u201d Pharmaceuticals (Basel, Switzerland). 2024;17(5):562.","DOI":"10.3390\/ph17050562"},{"issue":"5","key":"595_CR25","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1177\/10781552221104814","volume":"29","author":"MY Bektay","year":"2023","unstructured":"Bektay MY, et al. Comparison of different decision support software programs in perspective of potential drug-drug interactions in the oncology clinic. J Oncol Pharm Pract. 2023;29(5):1178\u201386.","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"595_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4103\/2279-042X.192461","volume":"5","author":"R Kheshti","year":"2016","unstructured":"Kheshti R, Aalipour M, Namazi S. A comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract. 2016;5(4):257\u201363.","journal-title":"J Res Pharm Pract"},{"issue":"1","key":"595_CR27","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1186\/s12885-018-5076-0","volume":"18","author":"LA Marcath","year":"2018","unstructured":"Marcath LA, et al. Prevalence of drug-drug interactions in oncology patients enrolled on National clinical trials network oncology clinical trials. BMC Cancer. 2018;18(1):1155.","journal-title":"BMC Cancer"},{"issue":"3","key":"595_CR28","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s11096-022-01385-9","volume":"44","author":"A Pehlivanli","year":"2022","unstructured":"Pehlivanli A, et al. Potential drug-drug interactions of immunosuppressants in kidney transplant recipients: comparison of drug interaction resources. Int J Clin Pharm. 2022;44(3):651\u201362.","journal-title":"Int J Clin Pharm"},{"issue":"10","key":"595_CR29","first-page":"1291","volume":"26","author":"K Tecen-Yucel","year":"2020","unstructured":"Tecen-Yucel K, et al. Assessment of clinically relevant drug interactions by online programs in renal transplant recipients. J Manag Care Spec Pharm. 2020;26(10):1291\u20136.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"595_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12882-016-0317-4","volume":"17","author":"R Al-Ramahi","year":"2016","unstructured":"Al-Ramahi R, et al. Evaluation of potential drug- drug interactions among Palestinian Hemodialysis patients. BMC Nephrol. 2016;17(1):96.","journal-title":"BMC Nephrol"},{"key":"595_CR31","doi-asserted-by":"publisher","first-page":"1473719","DOI":"10.3389\/fmed.2024.1473719","volume":"11","author":"B \u00d6zgan","year":"2024","unstructured":"\u00d6zgan B, et al. Clinical pharmacist interventions in nutrition-and drug-related problems in critically ill patients with renal dysfunction: a non-randomized controlled study. Front Med (Lausanne). 2024;11:1473719.","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"595_CR32","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/j.clinthera.2009.08.009","volume":"31","author":"EN van Roon","year":"2009","unstructured":"van Roon EN, et al. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists. Clin Ther. 2009;31(8):1737\u201346.","journal-title":"Clin Ther"},{"issue":"1","key":"595_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26650\/IstanbulJPharm.2020.0041","volume":"51","author":"N \u00d6zdemir","year":"2021","unstructured":"\u00d6zdemir N, et al. Evaluation of drug-drug interactions and their clinical importance in a pediatric hematopoietic stem cell transplantation unit. \u0130stanbul J Pharm. 2021;51(1):1\u20137.","journal-title":"\u0130stanbul J Pharm"},{"issue":"3","key":"595_CR34","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4103\/0975-1483.66807","volume":"2","author":"J Ansari","year":"2010","unstructured":"Ansari J. Drug interaction and pharmacist. J Young Pharm. 2010;2(3):326\u201331.","journal-title":"J Young Pharm"},{"issue":"3","key":"595_CR35","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/10781552241237750","volume":"31","author":"C Guzm\u00e1n Cordero","year":"2025","unstructured":"Guzm\u00e1n Cordero C, et al. Pharmacist\u2019s role in the management of drug-drug interactions caused by nirmatrelvir\/ritonavir in COVID-19 oncohematology patients. J Oncol Pharm Pract. 2025;31(3):374\u201380.","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"595_CR36","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s11096-019-00918-z","volume":"41","author":"KD Georgiev","year":"2019","unstructured":"Georgiev KD, et al. The role of the clinical pharmacist in the prevention of potential drug interactions in geriatric heart failure patients. Int J Clin Pharm. 2019;41(6):1555\u201361.","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"595_CR37","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s11096-014-0029-4","volume":"36","author":"C Lopez-Martin","year":"2014","unstructured":"Lopez-Martin C, et al. Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience. Int J Clin Pharm. 2014;36(6):1251\u20139.","journal-title":"Int J Clin Pharm"},{"key":"595_CR38","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/TCRM.S44205","volume":"9","author":"KA Oshikoya","year":"2013","unstructured":"Oshikoya KA, et al. Clinically significant interactions between antiretroviral and co-prescribed drugs for HIV-infected children: profiling and comparison of two drug databases. Ther Clin Risk Manag. 2013;9:215\u201321.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"595_CR39","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230.","journal-title":"BMC Geriatr"},{"issue":"1","key":"595_CR40","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159\u201374.","journal-title":"Biometrics"},{"issue":"5","key":"595_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.reuma.2024.02.006","volume":"20","author":"R Lozano-Lozano","year":"2024","unstructured":"Lozano-Lozano R, et al. Prevalence of polypharmacy and drug interaction in older adults with rheumatic disease. Reumatol Clin (Engl Ed). 2024;20(5):249\u201353.","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"4","key":"595_CR42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/msc.112","volume":"5","author":"GJ Treharne","year":"2007","unstructured":"Treharne GJ, et al. Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidity. Musculoskelet Care. 2007;5(4):175\u201390.","journal-title":"Musculoskelet Care"},{"issue":"3","key":"595_CR43","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/0897190019869158","volume":"34","author":"APM Gomides","year":"2021","unstructured":"Gomides APM, et al. High levels of polypharmacy in rheumatoid Arthritis-A challenge not covered by current management recommendations: data from a large Real-Life study. J Pharm Pract. 2021;34(3):365\u201371.","journal-title":"J Pharm Pract"},{"key":"595_CR44","doi-asserted-by":"publisher","first-page":"946415","DOI":"10.3389\/fphar.2022.946415","volume":"13","author":"M Zhao","year":"2022","unstructured":"Zhao M, et al. Potential drug-drug interactions in drug therapy for older adults with chronic coronary syndrome at hospital discharge: A real-world study. Front Pharmacol. 2022;13:946415.","journal-title":"Front Pharmacol"},{"issue":"11","key":"595_CR45","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s00228-015-1943-7","volume":"71","author":"GG Kongsholm","year":"2015","unstructured":"Kongsholm GG, Nielsen AK, Damkier P. Drug interaction databases in medical literature: transparency of ownership, funding, classification algorithms, level of documentation, and staff qualifications. A systematic review. Eur J Clin Pharmacol. 2015;71(11):1397\u2013402.","journal-title":"Eur J Clin Pharmacol"},{"issue":"13","key":"595_CR46","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: A review. JAMA. 2018;320(13):1360\u201372.","journal-title":"JAMA"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00595-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00595-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00595-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T06:31:49Z","timestamp":1788157909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-026-00595-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["595"],"URL":"https:\/\/doi.org\/10.1007\/s40199-026-00595-0","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Bet\u00fcl \u00d6zgan affiliation \" Department of Clinical Pharmacy, Faculty of Pharmacy, Marmara University, Istanbul, Turkey\" has been corrected in the original publication.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Language editing support for this manuscript was provided by an AI-based language model, which was used to improve grammar, clarity, and coherence. The final content was reviewed and approved by the authors to ensure accuracy and alignment with the original scientific intent.","order":2,"name":"Ethics","label":"Language editing statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"17"}}